Dr David Ribeiro, CEO of ProAxsis, will be attending the Bio-Europe Spring meeting, taking place in Barcelona on March 20th-22nd 2017, and will be presenting a company update at 11.15h on March 22nd in Room 118 on Level 1. This will be the 11th annual meeting of the international partnering conference.
Dr Ribeiro said: “As we’re actively seeking commercial partners for a number of our assets, events such as Bio-Europe Spring offer a key opportunity for us to interact with the pharmaceutical and investment community. With our ProteaseTag® Active Neutrophil Elastase Immunoassay now registered with a CE Mark in Europe, and our first point-of care test expected to launch this year, it is critical for the company to identify and reach agreements with companies that share our vision and goals for our exciting technology.”
Any requests from either pharmaceutical companies or academic researchers for support to measure active proteases or other inflammatory biomarkers can be directed to email@example.com.
ProAxsis is part of the NetScientific group and is one of the group’s core portfolio companies. The company is also supported by QUBIS, the commercialisation arm of Queens University.